Ahmed Bader*
Heart failure (HF) is a major leading cause of mortality and morbidity worldwide. The primary and secondary preventions of chronic heart failure are a priority for the health system and require multiple approaches to increase their effectiveness. Serum Cardiac Biomarkers are tools used to more accurately identify high-risk individuals of chronic Heart Failure, to speed the diagnosis, and to aid in treatment and prognosis determination. This review aims to highlight the importance of utilization of a variety of these cardiac biomarkers in assessment of asymptomatic HF patients, and decompensated symptomatic cases of chronic heart failure and to raise relevant points of their clinical use and the promises for the coming years for better management under different types of pharmacotherapeutic lines for treatment of chronic heart failure.
English 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi